Equities analysts expect CME Group Inc (NASDAQ:CME) to post $1.02 billion in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for CME Group’s earnings. The highest sales estimate is $1.03 billion and the lowest is $993.30 million. CME Group reported sales of $900.00 million during the same quarter last year, which would suggest a positive year over year growth rate of 13.3%. The business is expected to report its next quarterly earnings results on Thursday, February 7th.
According to Zacks, analysts expect that CME Group will report full year sales of $4.03 billion for the current fiscal year, with estimates ranging from $3.86 billion to $4.10 billion. For the next fiscal year, analysts anticipate that the company will post sales of $4.53 billion, with estimates ranging from $4.03 billion to $5.05 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that that provide coverage for CME Group.
CME Group (NASDAQ:CME) last posted its quarterly earnings results on Thursday, October 25th. The financial services provider reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.03. The business had revenue of $904.20 million during the quarter, compared to the consensus estimate of $910.50 million. CME Group had a net margin of 113.67% and a return on equity of 9.18%.
CME has been the subject of several recent research reports. Zacks Investment Research raised shares of CME Group from a “sell” rating to a “hold” rating in a research note on Wednesday, October 3rd. Bank of America reaffirmed a “buy” rating and set a $200.00 price objective on shares of CME Group in a research note on Monday, November 5th. Berenberg Bank raised shares of CME Group from a “hold” rating to a “buy” rating and set a $220.00 price objective for the company in a research note on Tuesday, November 20th. Jefferies Financial Group upped their price objective on shares of CME Group to $203.00 and gave the company a “buy” rating in a research note on Monday, October 8th. Finally, BidaskClub raised shares of CME Group from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 9th. Six analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $194.13.
CME Group stock opened at $187.11 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $63.96 billion, a price-to-earnings ratio of 39.23, a price-to-earnings-growth ratio of 2.19 and a beta of 0.46. CME Group has a twelve month low of $143.68 and a twelve month high of $197.08.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 27th. Investors of record on Monday, December 10th will be given a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.50%. The ex-dividend date of this dividend is Friday, December 7th. CME Group’s dividend payout ratio is currently 58.70%.
In other CME Group news, Director Charles P. Carey sold 2,800 shares of the company’s stock in a transaction dated Friday, November 2nd. The shares were sold at an average price of $183.45, for a total value of $513,660.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Martin J. Gepsman sold 300 shares of the company’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $172.30, for a total transaction of $51,690.00. Following the completion of the sale, the director now owns 42,912 shares in the company, valued at approximately $7,393,737.60. The disclosure for this sale can be found here. Insiders have sold 29,800 shares of company stock worth $5,628,462 in the last quarter. 0.43% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in CME Group by 1.8% in the third quarter. BlackRock Inc. now owns 22,422,112 shares of the financial services provider’s stock worth $3,816,468,000 after purchasing an additional 403,327 shares during the period. Capital International Investors grew its holdings in CME Group by 18.3% in the third quarter. Capital International Investors now owns 15,425,378 shares of the financial services provider’s stock worth $2,625,554,000 after purchasing an additional 2,383,280 shares during the period. Capital Research Global Investors grew its holdings in CME Group by 107.8% in the third quarter. Capital Research Global Investors now owns 10,906,683 shares of the financial services provider’s stock worth $1,856,427,000 after purchasing an additional 5,658,108 shares during the period. Edgewood Management LLC grew its holdings in CME Group by 9.5% in the third quarter. Edgewood Management LLC now owns 8,582,518 shares of the financial services provider’s stock worth $1,460,830,000 after purchasing an additional 742,067 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in CME Group by 3.3% in the third quarter. Janus Henderson Group PLC now owns 6,331,522 shares of the financial services provider’s stock worth $1,077,689,000 after purchasing an additional 202,365 shares during the period. Institutional investors and hedge funds own 85.89% of the company’s stock.
CME Group Company Profile
CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals.
Recommended Story: Should You Consider an Index Fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.